Lee J, et al. - In this retrospective analysis, researchers focused on clinicopathological features and outcomes of 17 patients who received mesna, doxorubicin, ifosfamide, and dacarbazine (MAID) for advanced pulmonary pleomorphic carcinoma (PC) between January 2010 and February 2017. They found that median PFS was 2.8 months and the median OS was 8.7 months. The most frequently reported adverse events were attributed to hematologic toxicity, which included grade 3-4 anemia in 35% of patients, neutropenia in 47%, thrombocytopenia in 24%, and febrile neutropenia in 29%. Overall, MAID showed efficacy as a treatment regimen for PC. A safer use of MAID is possible in clinical practice via appropriate dose modifications and granulocyte-colony stimulating factor primary prophylaxis according to patients’ status.